New Jersey A1816 mandates hospitals to test for fentanyl and xylazine in urine drug screenings.

New Jersey A1816 requires hospitals to include fentanyl and xylazine testing in urine drug screenings. This bill aims to detect these drugs, which are linked to increased overdose deaths, by requiring hospitals to test for them and report results to the Department of Health. The screening must also test for any drug for which the Commissioner of Health has issued a public health alert on overdose risks. This measure seeks to improve patient treatment by ensuring hospitals are aware of the presence of these dangerous substances.

New Jersey A1816 mandates hospitals to test for fentanyl and xylazine in urine drug screenings.

New Jersey A1816 requires hospitals to include fentanyl and xylazine testing in urine drug screenings. This bill aims to detect these drugs, which are linked to increased overdose deaths, by requiring hospitals to test for them and report results to the Department of Health. The screening must also test for any drug for which the Commissioner of Health has issued a public health alert on overdose risks. This measure seeks to improve patient treatment by ensuring hospitals are aware of the presence of these dangerous substances.